Malignant : how bad policy and bad evidence harm people with cancer / Vinayak K. Prasad.

By:

Prasad, Vinayak K, 1982- [Author]

Material type: Text

text

Media type:

computer

Carrier type:

online resource

ISBN:

9781421437644

Other title:

How bad policy and bad evidence harm people with cancer

Subject(s):

Genre/Form:

Electronic Books.

LOC classification:

RC271 .M355 2020

Online resources:

Click to access digital title | log in using your CIU ID number and my.ciu.edu password

Available additional physical forms:

Contents:

Surrogate Endpoints in Cancer : What Are They and Where Are They Used? -- Use and Misuse of Surrogates for Drug Approvals -- How High Prices Harm Patients and Society -- Hype, Spin, and the Unbridled Enthusiasm That Distorts Cancer Medicine -- Financial Conflict of Interest -- The Harms of Financial Conflicts and How to Rehabilitate Medicine -- Will Precision Oncology Save Us? -- Study Design -- Principles of Oncology Practice -- Important Trials in Oncology -- Global Oncology -- How Should Cancer Drug Development Proceed? -- What Can the US Food and Drug Administration and the Centers for Medicare and -- Medicaid Services Do Tomorrow? -- What Can People with Cancer Do? -- What Can Students, Residents, and Fellows Do?

Subject: "In this critical study of current cancer therapies, Dr. Prasad, an oncologist and hematologist, examines oncology practice and policy in the United States. His book is organized into four sections: (1) an overview of cancer drugs, (2) forces that distort cancer medicine and practice, (3) details about cancer research and practice, (4) recommended solutions on multiple levels (policy, practitioners, medical education, and pharmacology)"--

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Collection	Call number	URL	Status	Date due	Barcode
Online Book (LOGIN USING YOUR MY CIU LOGIN AND PASSWORD)	G. Allen Fleece Library ONLINE	Non-fiction	RC271.5 (Browse shelf(Opens below))	Link to resource	Available		on1151401571

Browsing G. Allen Fleece Library shelves, Shelving location: ONLINE, Collection: Non-fiction Close shelf browser (Hides shelf browser)

Previous								Next
Previous	RC271.3 Precision radiation oncology /edited by Bruce G. Hafty and Sharad Goyal.	RC271.45 Exploring the state of the science of stem cell transplantation and posttransplant disability : proceedings of a workshop /	RC271.5 Oncology pharmacy practice : the clinical pharmacist's perspective /	RC271.5 Malignant : how bad policy and bad evidence harm people with cancer /	RC271.53 How plant flavonoids affect the outcome of hormonal and biological cancer therapies : a handbook for doctors and patients /	RC275 Innovation in Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic Proceedings of a Workshop.	RC275 Malignant growth : creating the modern cancer research establishment, 1875-1915 /	Next

Includes bibliographies and index.

The Basics of Cancer Drugs : Cost, Benefit, Value -- Surrogate Endpoints in Cancer : What Are They and Where Are They Used? -- Use and Misuse of Surrogates for Drug Approvals -- How High Prices Harm Patients and Society -- Hype, Spin, and the Unbridled Enthusiasm That Distorts Cancer Medicine -- Financial Conflict of Interest -- The Harms of Financial Conflicts and How to Rehabilitate Medicine -- Will Precision Oncology Save Us? -- Study Design -- Principles of Oncology Practice -- Important Trials in Oncology -- Global Oncology -- How Should Cancer Drug Development Proceed? -- What Can the US Food and Drug Administration and the Centers for Medicare and -- Medicaid Services Do Tomorrow? -- What Can People with Cancer Do? -- What Can Students, Residents, and Fellows Do?

"In this critical study of current cancer therapies, Dr. Prasad, an oncologist and hematologist, examines oncology practice and policy in the United States. His book is organized into four sections: (1) an overview of cancer drugs, (2) forces that distort cancer medicine and practice, (3) details about cancer research and practice, (4) recommended solutions on multiple levels (policy, practitioners, medical education, and pharmacology)"--